Johnson & Johnson (JNJ)
Johnson & Johnson (JNJ) Stock Dips While Market Gains: Key Facts
Johnson & Johnson (JNJ) closed the most recent trading day at $146.76, moving -0.25% from the previous trading session.
7 Recession-Proof Stocks to Buy Now for Peace of Mind
Maintaining stability and security in investment portfolios is vital in an adverse macroeconomic environment. For instance, the current higher-for-longer interest rate environment coupled with other volatile macro elements may lead stocks into an unexpected and sudden downfall.
Johnson & Johnson reaches $700 million talc settlement with US states
Johnson & Johnson has agreed to pay $700 million to settle an investigation by 42 U.S. states and Washington, D.C. into its marketing of baby powder and other products that contained talc.
J&J-backed Rapport Therapeutics valued at $636.8 mln after shares rise 6% in debut
Shares of Rapport Therapeutics , backed by Johnson & Johnson's venture capital arm, rose nearly 6% in their market debut on Friday, valuing the early stage therapy developer at $636.8 million.
J&J-backed Rapport Therapeutics raises $136 mln in US IPO
Rapport Therapeutics said on Thursday that it has raised $136 million in its initial public offering in the United States at a valuation of about $601.4 million.
Johnson & Johnson (JNJ) Stock Drops Despite Market Gains: Important Facts to Note
Johnson & Johnson (JNJ) closed at $145.97 in the latest trading session, marking a -1.24% move from the prior day.
J&J (JNJ) Seeks Expanded Use of HIV Drug in US and Europe
J&J (JNJ) seeks expanded use of its HIV-1 therapy, Prezcobix, for younger kids in the United States and Europe.
3 Dividend Aristocrats to Scoop Up During Market Pullbacks in June
If you are worried about the economy and how the market will move from here, it is ideal to invest in dividend stocks that pay, no matter the market situation. When you have dividend aristocrat stocks in your portfolio, you can ensure consistent payouts for years.
J&J must pay $260 million in latest talc trial, Oregon jury says
Johnson & Johnson must pay $260 million in the case of an Oregon woman who said she got mesothelioma from inhaling the company's talc powder, a jury found on Monday.
J&J-backed Rapport Therapeutics seeks about $637 mln valuation in US IPO
Rapport Therapeutics is targeting a valuation of about $637 million in its initial public offering in the United States, as the biopharmaceutical company joins a slew of firms looking to list their shares amid a rebound in the capital markets.
3 Magnificent Dividend Stocks to Buy and Hold Forever
Johnson & Johnson is a Dividend King that's investing heavily in R&D and making smart acquisitions. Target is another Dividend King that continually looks for new ways to boost sales.
Johnson & Johnson: Market Will Regret The Overreaction
Johnson & Johnson stock prices have been consistently declining in the recent 1~2 years. The stock is currently undervalued, with lower P/E ratios compared to the sector median and historical averages, and a high dividend yield. Yet, Johnson & Johnson's profitability remains strong, and there are potential catalysts for growth, including the adoption of new products and potential acquisitions.
